As you transition from clinical to commercial biologic manufacturing, you are on a complex – yet exciting – journey as you are nearing the market and helping patients in need. Now is the time to make important decisions that will impact your commercial success.
How do you minimize risk and maximize process efficiency? Our Vice President Sébastien Ribault, Ph.D., and R-Pharm’s International Marketing Director Kira Ivanova will talk about our CDMO partnership and how the combination of our late-stage CDMO capabilities, single-use technology, and tailored guidance help prepare for production and, ultimately, accelerate and streamline R-Pharm’s commercial manufacturing process for olokizumab.
In this virtual event, you will discover more about:
<ul>
<li>Flexible CDMO solutions and guidance on the journey from clinical to commercial production</li>
<li>Our global network of labs, facilities, and ongoing expansions</li>
<li>How R-Pharm leverages our CDMO partnership to help accelerate market readiness of olokizumab</li>
</ul>

aem-GridColumn aem-GridColumn--default--9

<h2 class="webinar-subtitle">WEBINAR</h2>

CDMO Case Study: Single-Use Manufacturing

aem-GridColumn aem-GridColumn--default--9 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

aem-GridColumn aem-GridColumn--default--3 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

R-Pharm accelerates market readiness for biologics through CDMO partnership, minimizing risk and maximizing efficiency in manufacturing.